drugset / Trial / NCT02822534
The Pharmacokinetics and Pharmacodynamics Study of Single and Multiple Dose of SP2086 in Type 2 Diabetes Patients
Non-randomizedFactorialOpen-labelTreatment
Summary
SP2086 is a novel inhibitor of Dipeptide base peptidase 4, allows an insulin-independent approach to improve type 2 diabetes hyperglycemia. In this single-dose and multiple-dose study the investigators evaluated the safety, tolerability and PK/PD profiles of SP2086 in Type 2 Diabetes Patients .
Timeline
- Start
- 2016-04
- Primary completion
- 2016-07
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Retagliptin | Small molecule | 50 mg | — |
| Subject | Retagliptin | Small molecule | 100 mg | — |
| Subject | Retagliptin | Small molecule | 200 mg | — |